PL3197466T3 - Kombinacja kinureniny i komórek prezentujących antygen (antigen presenting cells, apc) jako środków terapeutycznych i sposoby ich stosowania w modulacji układu odpornościowego - Google Patents

Kombinacja kinureniny i komórek prezentujących antygen (antigen presenting cells, apc) jako środków terapeutycznych i sposoby ich stosowania w modulacji układu odpornościowego

Info

Publication number
PL3197466T3
PL3197466T3 PL15844259T PL15844259T PL3197466T3 PL 3197466 T3 PL3197466 T3 PL 3197466T3 PL 15844259 T PL15844259 T PL 15844259T PL 15844259 T PL15844259 T PL 15844259T PL 3197466 T3 PL3197466 T3 PL 3197466T3
Authority
PL
Poland
Prior art keywords
kynurenine
apc
therapeutics
methods
combination
Prior art date
Application number
PL15844259T
Other languages
English (en)
Inventor
Aziz Ghahary
Reza B. JALILI
Ruhangiz T. Kilani
Yunyuan LI
Original Assignee
The University Of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of British Columbia filed Critical The University Of British Columbia
Publication of PL3197466T3 publication Critical patent/PL3197466T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
PL15844259T 2014-09-26 2015-09-25 Kombinacja kinureniny i komórek prezentujących antygen (antigen presenting cells, apc) jako środków terapeutycznych i sposoby ich stosowania w modulacji układu odpornościowego PL3197466T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462055823P 2014-09-26 2014-09-26
US201462087156P 2014-12-03 2014-12-03
PCT/CA2015/000506 WO2016044922A1 (en) 2014-09-26 2015-09-25 A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation
EP15844259.0A EP3197466B1 (en) 2014-09-26 2015-09-25 A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation

Publications (1)

Publication Number Publication Date
PL3197466T3 true PL3197466T3 (pl) 2021-09-13

Family

ID=55579987

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15844259T PL3197466T3 (pl) 2014-09-26 2015-09-25 Kombinacja kinureniny i komórek prezentujących antygen (antigen presenting cells, apc) jako środków terapeutycznych i sposoby ich stosowania w modulacji układu odpornościowego

Country Status (14)

Country Link
US (2) US12551459B2 (pl)
EP (1) EP3197466B1 (pl)
JP (1) JP6898228B2 (pl)
AU (1) AU2015321365B2 (pl)
CA (1) CA2962655C (pl)
CY (1) CY1124162T1 (pl)
DK (1) DK3197466T3 (pl)
ES (1) ES2867301T3 (pl)
HU (1) HUE054020T2 (pl)
MX (1) MX386164B (pl)
PL (1) PL3197466T3 (pl)
PT (1) PT3197466T (pl)
RU (1) RU2727573C2 (pl)
WO (1) WO2016044922A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018044724A1 (en) * 2016-08-31 2018-03-08 Ampio Pharmaceuticals, Inc. Treatment of disease with n-acetyl kynurenine
WO2019178013A1 (en) * 2018-03-14 2019-09-19 Albert Einstein College Of Medicine Immunoregulatory role of 3-oh-kynurenamine and uses thereof
AU2019371463B2 (en) * 2018-11-04 2025-06-26 Figene, Llc Methods and compositions for treatment of type 1 diabetes using fibroblasts as facilitators of islet engraftment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
AU2002952834A0 (en) 2002-09-16 2002-12-05 The Walter And Eliza Hall Institute Of Medical Research A method of treating an autoimmune disease
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
US9228172B2 (en) * 2008-06-19 2016-01-05 The Trustees Of The University Of Pennsylvania Inducible regulatory T-cell generation for hematopoietic transplants
WO2010002993A1 (en) 2008-07-01 2010-01-07 Genocea Biosciences, Inc. Antigen screening system
BRPI0916576A2 (pt) * 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
ITRM20080529A1 (it) * 2008-10-07 2010-04-08 Uni Degli Studi Perugia Uso della l-chinurenina e suoi derivati per la prevenzione ed il trattamento del diabete mellito di tipo 1.
WO2012007950A2 (en) * 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
EP2694643A1 (en) 2011-04-08 2014-02-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Culture medium and method for obtaining a population of tolerogenic dendritic cells
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
GB201211120D0 (en) * 2012-06-22 2012-08-01 Bessede Alban Antagonist to an enzyme and/or a metabolite of the kynurenine pathway
JP2014111631A (ja) 2014-01-31 2014-06-19 Tella Inc 樹状細胞の培養方法

Also Published As

Publication number Publication date
AU2015321365A1 (en) 2017-04-20
HUE054020T2 (hu) 2021-08-30
CY1124162T1 (el) 2022-05-27
CA2962655A1 (en) 2016-03-31
DK3197466T3 (da) 2021-05-10
US20230414550A1 (en) 2023-12-28
CA2962655C (en) 2022-08-09
EP3197466A1 (en) 2017-08-02
RU2017114206A3 (pl) 2019-04-30
JP6898228B2 (ja) 2021-07-07
AU2015321365B2 (en) 2021-05-20
EP3197466A4 (en) 2018-05-30
ES2867301T3 (es) 2021-10-20
MX2017003808A (es) 2017-12-15
PT3197466T (pt) 2021-05-14
RU2727573C2 (ru) 2020-07-22
JP2017528508A (ja) 2017-09-28
WO2016044922A1 (en) 2016-03-31
MX386164B (es) 2025-03-18
EP3197466B1 (en) 2021-02-17
US20170209401A1 (en) 2017-07-27
US12551459B2 (en) 2026-02-17
RU2017114206A (ru) 2018-10-26

Similar Documents

Publication Publication Date Title
IL286282A (en) Use of palinabolin in combination with immune checkpoint inhibitors
SG11201703203RA (en) Methods and compositions for dosing in adoptive cell therapy
IL251951A0 (en) Methods and compositions for natural killer cells
IL253248A0 (en) Natural killer cells and their uses
SG11201609118RA (en) Modified natural killer cells and uses thereof
IL251128A0 (en) Bispecific antibodies and methods of use in ophthalmology
ZA201703443B (en) Oral rehydration composition and methods thereof
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
EP3107996A4 (en) Tscm cells and methods for use
IL252686A0 (en) Pyrazolopyridineamines as inhibitors of mknk1 and mknk2
GB201416293D0 (en) Methods and preparations
IL279583B (en) Methods for preparing poloxamer for use in cell culture medium
IL244750A0 (en) Autologous tumor vaccines and methods
SG11201702475VA (en) Methods and compositions for modulating th-gm cell function
PL3215143T3 (pl) Połączenie zawierające spirulinę i palmitoiloetanoloamid
PT2944309T (pt) Utilização de palmitoiletanolamida em combinação com opióides
PT3197466T (pt) Combinação de quinurenina e células apresentadoras de antígeno (apc) como agentes terapêuticos e métodos para seu uso na modulação imunológica
EP3194279A4 (en) Distribution of coins in bags
EP3194278A4 (en) Distribution of coins in bags
GB201410423D0 (en) Improvements in and relating to steam stations
GB2530075B (en) Improvements in and relating to eyewashing
GB201409548D0 (en) Methods and apparatuses relating to injection-moulded objects
GB201419239D0 (en) Methods and apparatus relating to injection-moulded objects
GB201417432D0 (en) Improvements in and relating to pipe-breaking
GB201415759D0 (en) Accelerator compositions and methods